Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up.

Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, FitzGerald DJ, Santiago L, Gao G, Lanasa MC, Pastan I.

Blood. 2018 May 24;131(21):2331-2334. doi: 10.1182/blood-2017-09-803072. Epub 2018 Feb 27.

PMID:
29487070
2.

Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia.

Wayne AS, Shah NN, Bhojwani D, Silverman LB, Whitlock JA, Stetler-Stevenson M, Sun W, Liang M, Yang J, Kreitman RJ, Lanasa MC, Pastan I.

Blood. 2017 Oct 5;130(14):1620-1627. doi: 10.1182/blood-2017-02-749101. Epub 2017 Aug 9.

PMID:
28983018
3.

Characteristics and treatment patterns among US patients with hairy cell leukemia: a retrospective claims analysis.

Divino V, Karve S, Gaughan A, DeKoven M, Gao G, Knopf KB, Lanasa MC.

J Comp Eff Res. 2017 Sep;6(6):497-508. doi: 10.2217/cer-2017-0014. Epub 2017 May 9.

4.

Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia.

Lanasa MC, Andritsos L, Brown JR, Gabrilove J, Caligaris-Cappio F, Ghia P, Larson RA, Kipps TJ, Leblond V, Milligan DW, Janssens A, Johnson AJ, Heerema NA, Bühler A, Stilgenbauer S, Devin J, Hallek M, Byrd JC, Grever MR.

Leuk Res. 2015 May;39(5):495-500. doi: 10.1016/j.leukres.2015.02.001. Epub 2015 Feb 7.

5.

Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR(™) therapeutic protein, for relapsed or refractory NHL patients.

Pagel JM, Spurgeon SE, Byrd JC, Awan FT, Flinn IW, Lanasa MC, Eisenfeld AJ, Stromatt SC, Gopal AK.

Br J Haematol. 2015 Jan;168(1):38-45. doi: 10.1111/bjh.13099. Epub 2014 Aug 22.

PMID:
25146490
6.

Mitochondrial priming of chronic lymphocytic leukemia patients associates Bcl-xL dependence with alvocidib response.

Pierceall WE, Warner SL, Lena RJ, Doykan C, Blake N, Elashoff M, Hoff DV, Bearss DJ, Cardone MH, Andritsos L, Byrd JC, Lanasa MC, Grever MR, Johnson AJ.

Leukemia. 2014 Nov;28(11):2251-4. doi: 10.1038/leu.2014.206. Epub 2014 Jul 3. No abstract available.

7.

Clinical characteristics, response to therapy, and survival of African American patients diagnosed with chronic lymphocytic leukemia: joint experience of the MD Anderson Cancer Center and Duke University Medical Center.

Falchi L, Keating MJ, Wang X, Coombs CC, Lanasa MC, Strom S, Wierda WG, Ferrajoli A.

Cancer. 2013 Sep 1;119(17):3177-85. doi: 10.1002/cncr.28030. Epub 2013 Jul 8.

8.

Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL).

Shanafelt T, Lanasa MC, Call TG, Beaven AW, Leis JF, LaPlant B, Bowen D, Conte M, Jelinek DF, Hanson CA, Kay NE, Zent CS.

Cancer. 2013 Nov 1;119(21):3788-96. doi: 10.1002/cncr.28292. Epub 2013 Aug 6. Erratum in: Cancer. 2014 Mar 15;120(6):926. Dosage error in article text.

9.

Perifosine treatment in chronic lymphocytic leukemia: results of a phase II clinical trial and in vitro studies.

Friedman DR, Lanasa MC, Davis PH, Allgood SD, Matta KM, Brander DM, Chen Y, Davis ED, Volkheimer AD, Moore JO, Gockerman JP, Sportelli P, Weinberg JB.

Leuk Lymphoma. 2014 May;55(5):1067-75. doi: 10.3109/10428194.2013.824080. Epub 2013 Aug 31.

PMID:
23863122
10.

Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia.

Berndt SI, Skibola CF, Joseph V, Camp NJ, Nieters A, Wang Z, Cozen W, Monnereau A, Wang SS, Kelly RS, Lan Q, Teras LR, Chatterjee N, Chung CC, Yeager M, Brooks-Wilson AR, Hartge P, Purdue MP, Birmann BM, Armstrong BK, Cocco P, Zhang Y, Severi G, Zeleniuch-Jacquotte A, Lawrence C, Burdette L, Yuenger J, Hutchinson A, Jacobs KB, Call TG, Shanafelt TD, Novak AJ, Kay NE, Liebow M, Wang AH, Smedby KE, Adami HO, Melbye M, Glimelius B, Chang ET, Glenn M, Curtin K, Cannon-Albright LA, Jones B, Diver WR, Link BK, Weiner GJ, Conde L, Bracci PM, Riby J, Holly EA, Smith MT, Jackson RD, Tinker LF, Benavente Y, Becker N, Boffetta P, Brennan P, Foretova L, Maynadie M, McKay J, Staines A, Rabe KG, Achenbach SJ, Vachon CM, Goldin LR, Strom SS, Lanasa MC, Spector LG, Leis JF, Cunningham JM, Weinberg JB, Morrison VA, Caporaso NE, Norman AD, Linet MS, De Roos AJ, Morton LM, Severson RK, Riboli E, Vineis P, Kaaks R, Trichopoulos D, Masala G, Weiderpass E, Chirlaque MD, Vermeulen RC, Travis RC, Giles GG, Albanes D, Virtamo J, Weinstein S, Clavel J, Zheng T, Holford TR, Offit K, Zelenetz A, Klein RJ, Spinelli JJ, Bertrand KA, Laden F, Giovannucci E, Kraft P, Kricker A, Turner J, Vajdic CM, Ennas MG, Ferri GM, Miligi L, Liang L, Sampson J, Crouch S, Park JH, North KE, Cox A, Snowden JA, Wright J, Carracedo A, Lopez-Otin C, Bea S, Salaverria I, Martin-Garcia D, Campo E, Fraumeni JF Jr, de Sanjose S, Hjalgrim H, Cerhan JR, Chanock SJ, Rothman N, Slager SL.

Nat Genet. 2013 Aug;45(8):868-76. doi: 10.1038/ng.2652. Epub 2013 Jun 16.

11.

Highlights of the 7th young investigators' meeting on chronic lymphocytic leukemia.

Lanasa MC, Kater AP, Shanafelt T, Fischer K.

Leuk Lymphoma. 2013 Aug;54(8):1815-6. doi: 10.3109/10428194.2013.796054. Epub 2013 May 29. No abstract available.

PMID:
23597136
12.

Mapping of the IRF8 gene identifies a 3'UTR variant associated with risk of chronic lymphocytic leukemia but not other common non-Hodgkin lymphoma subtypes.

Slager SL, Achenbach SJ, Asmann YW, Camp NJ, Rabe KG, Goldin LR, Call TG, Shanafelt TD, Kay NE, Cunningham JM, Wang AH, Weinberg JB, Norman AD, Link BK, Leis JF, Vachon CM, Lanasa MC, Caporaso NE, Novak AJ, Cerhan JR.

Cancer Epidemiol Biomarkers Prev. 2013 Mar;22(3):461-6. doi: 10.1158/1055-9965.EPI-12-1217. Epub 2013 Jan 10.

13.

Genetic evidence of PTPN22 effects on chronic lymphocytic leukemia.

Hebbring SJ, Slager SL, Epperla N, Mazza JJ, Ye Z, Zhou Z, Achenbach SJ, Vasco DA, Call TG, Rabe KG, Kay NE, Caporaso NE, Lanasa MC, Camp NJ, Strom SS, Goldin LR, Cerhan JR, Brilliant MH, Schrodi SJ.

Blood. 2013 Jan 3;121(1):237-8. doi: 10.1182/blood-2012-08-450221. No abstract available.

14.

Common variants within 6p21.31 locus are associated with chronic lymphocytic leukaemia and, potentially, other non-Hodgkin lymphoma subtypes.

Slager SL, Camp NJ, Conde L, Shanafelt TD, Achenbach SJ, Rabe KG, Kay NE, Novak AJ, Call TG, Bracci PM, Sille FM, Sanchez S, Akers NK, Cunningham JM, Serie DJ, McDonnell SK, Leis JF, Wang AH, Weinberg JB, Glenn M, Link B, Vachon CM, Lanasa MC, Skibola CF, Cerhan JR.

Br J Haematol. 2012 Dec;159(5):572-6. doi: 10.1111/bjh.12070. Epub 2012 Oct 1.

15.

Single nucleotide polymorphisms and inherited risk of chronic lymphocytic leukemia among African Americans.

Coombs CC, Rassenti LZ, Falchi L, Slager SL, Strom SS, Ferrajoli A, Weinberg JB, Kipps TJ, Lanasa MC.

Blood. 2012 Aug 23;120(8):1687-90. doi: 10.1182/blood-2012-02-408799. Epub 2012 Jun 28.

16.

Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function.

DiLillo DJ, Weinberg JB, Yoshizaki A, Horikawa M, Bryant JM, Iwata Y, Matsushita T, Matta KM, Chen Y, Venturi GM, Russo G, Gockerman JP, Moore JO, Diehl LF, Volkheimer AD, Friedman DR, Lanasa MC, Hall RP, Tedder TF.

Leukemia. 2013 Jan;27(1):170-82. doi: 10.1038/leu.2012.165. Epub 2012 Jul 13.

17.

Common variation at 6p21.31 (BAK1) influences the risk of chronic lymphocytic leukemia.

Slager SL, Skibola CF, Di Bernardo MC, Conde L, Broderick P, McDonnell SK, Goldin LR, Croft N, Holroyd A, Harris S, Riby J, Serie DJ, Kay NE, Call TG, Bracci PM, Halperin E, Lanasa MC, Cunningham JM, Leis JF, Morrison VA, Spector LG, Vachon CM, Shanafelt TD, Strom SS, Camp NJ, Weinberg JB, Matutes E, Caporaso NE, Wade R, Dyer MJ, Dearden C, Cerhan JR, Catovsky D, Houlston RS.

Blood. 2012 Jul 26;120(4):843-6. doi: 10.1182/blood-2012-03-413591. Epub 2012 Jun 13.

18.

Chronic lymphocytic leukemia in African Americans.

Coombs CC, Falchi L, Weinberg JB, Ferrajoli A, Lanasa MC.

Leuk Lymphoma. 2012 Nov;53(11):2326-9. doi: 10.3109/10428194.2012.698276. Epub 2012 Jul 9. Review.

PMID:
22646816
19.

Clinical aspects of monoclonal B-cell lymphocytosis.

Mowery YM, Lanasa MC.

Cancer Control. 2012 Jan;19(1):8-17. Review.

PMID:
22143058
20.

SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target.

Christensen DJ, Chen Y, Oddo J, Matta KM, Neil J, Davis ED, Volkheimer AD, Lanasa MC, Friedman DR, Goodman BK, Gockerman JP, Diehl LF, de Castro CM, Moore JO, Vitek MP, Weinberg JB.

Blood. 2011 Oct 13;118(15):4150-8. doi: 10.1182/blood-2011-04-351072. Epub 2011 Aug 15.

21.

Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia.

Lanasa MC, Davis PH, Datto M, Li Z, Gockerman JP, Moore JO, DeCastro CM, Friedman DR, Diehl LF, Rehder C, Cook H, Daugherty FJ, Matta KM, Weinberg JB, Rizzieri D.

Leuk Lymphoma. 2012 Feb;53(2):218-24. doi: 10.3109/10428194.2011.610012. Epub 2011 Sep 23.

PMID:
21827374
22.

Immunoglobulin class switch recombination in chronic lymphocytic leukemia.

Lanasa MC, Weinberg JB.

Leuk Lymphoma. 2011 Jul;52(7):1398-400. doi: 10.3109/10428194.2011.568076. Review.

PMID:
21699386
23.

Immunophenotypic and gene expression analysis of monoclonal B-cell lymphocytosis shows biologic characteristics associated with good prognosis CLL.

Lanasa MC, Allgood SD, Slager SL, Dave SS, Love C, Marti GE, Kay NE, Hanson CA, Rabe KG, Achenbach SJ, Goldin LR, Camp NJ, Goodman BK, Vachon CM, Spector LG, Rassenti LZ, Leis JF, Gockerman JP, Strom SS, Call TG, Glenn M, Cerhan JR, Levesque MC, Weinberg JB, Caporaso NE.

Leukemia. 2011 Sep;25(9):1459-66. doi: 10.1038/leu.2011.117. Epub 2011 May 27.

24.

Novel insights into the biology of CLL.

Lanasa MC.

Hematology Am Soc Hematol Educ Program. 2010;2010:70-6. doi: 10.1182/asheducation-2010.1.70. Review.

PMID:
21239773
25.

Immunologic aspects of monoclonal B-cell lymphocytosis.

Lanasa MC, Weinberg JB.

Immunol Res. 2011 Apr;49(1-3):269-80. doi: 10.1007/s12026-010-8188-4. Review.

26.

Genome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLL.

Slager SL, Rabe KG, Achenbach SJ, Vachon CM, Goldin LR, Strom SS, Lanasa MC, Spector LG, Rassenti LZ, Leis JF, Camp NJ, Glenn M, Kay NE, Cunningham JM, Hanson CA, Marti GE, Weinberg JB, Morrison VA, Link BK, Call TG, Caporaso NE, Cerhan JR.

Blood. 2011 Feb 10;117(6):1911-6. doi: 10.1182/blood-2010-09-308205. Epub 2010 Dec 3.

27.

Commentary: Comparison of current flow cytometry methods for monoclonal B cell lymphocytosis detection.

Nieto WG, Almeida J, Teodosio C, Abbasi F, Allgood SD, Connors F, Rachel JM, Ghia P, Lanasa MC, Rawstron AC, Orfao A, Caporaso NE, Hanson CA, Shim YK, Vogt RF, Marti GE.

Cytometry B Clin Cytom. 2010;78 Suppl 1:S4-9. doi: 10.1002/cyto.b.20556.

28.

Different biology and clinical outcome according to the absolute numbers of clonal B-cells in monoclonal B-cell lymphocytosis (MBL).

Rawstron AC, Shanafelt T, Lanasa MC, Landgren O, Hanson C, Orfao A, Hillmen P, Ghia P.

Cytometry B Clin Cytom. 2010;78 Suppl 1:S19-23. doi: 10.1002/cyto.b.20533. Review.

29.

Common occurrence of monoclonal B-cell lymphocytosis among members of high-risk CLL families.

Goldin LR, Lanasa MC, Slager SL, Cerhan JR, Vachon CM, Strom SS, Camp NJ, Spector LG, Leis JF, Morrison VA, Glenn M, Rabe KG, Achenbach SJ, Algood SD, Abbasi F, Fontaine L, Yau M, Rassenti LZ, Kay NE, Call TG, Hanson CA, Weinberg JB, Marti GE, Caporaso NE.

Br J Haematol. 2010 Oct;151(2):152-8. doi: 10.1111/j.1365-2141.2010.08339.x. Epub 2010 Aug 25.

30.

Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32.

Conde L, Halperin E, Akers NK, Brown KM, Smedby KE, Rothman N, Nieters A, Slager SL, Brooks-Wilson A, Agana L, Riby J, Liu J, Adami HO, Darabi H, Hjalgrim H, Low HQ, Humphreys K, Melbye M, Chang ET, Glimelius B, Cozen W, Davis S, Hartge P, Morton LM, Schenk M, Wang SS, Armstrong B, Kricker A, Milliken S, Purdue MP, Vajdic CM, Boyle P, Lan Q, Zahm SH, Zhang Y, Zheng T, Becker N, Benavente Y, Boffetta P, Brennan P, Butterbach K, Cocco P, Foretova L, Maynadié M, de Sanjosé S, Staines A, Spinelli JJ, Achenbach SJ, Call TG, Camp NJ, Glenn M, Caporaso NE, Cerhan JR, Cunningham JM, Goldin LR, Hanson CA, Kay NE, Lanasa MC, Leis JF, Marti GE, Rabe KG, Rassenti LZ, Spector LG, Strom SS, Vachon CM, Weinberg JB, Holly EA, Chanock S, Smith MT, Bracci PM, Skibola CF.

Nat Genet. 2010 Aug;42(8):661-4. doi: 10.1038/ng.626. Epub 2010 Jul 18.

31.

Monoclonal B cell lymphocytosis.

Lanasa MC, Allgood SD, Weinberg JB.

Leuk Lymphoma. 2010 Aug;51(8):1386-8. doi: 10.3109/10428194.2010.496018.

PMID:
20629528
32.

LMP-420: a novel purine nucleoside analog with potent cytotoxic effects for CLL cells and minimal toxicity for normal hematopoietic cells.

Mowery YM, Weinberg JB, Kennedy MN, Bond KM, Moore JO, Lanasa MC, Gockerman JP, Diehl LF, Pizzo SV, Cianciolo GJ, Friedman DR.

Leukemia. 2010 Sep;24(9):1580-7. doi: 10.1038/leu.2010.150. Epub 2010 Jul 8.

PMID:
20613784
33.

Genetic susceptibility variants for chronic lymphocytic leukemia.

Slager SL, Goldin LR, Strom SS, Lanasa MC, Spector LG, Rassenti L, Leis JF, Camp NJ, Kay NE, Vachon CM, Glenn M, Weinberg JB, Rabe KG, Cunningham JM, Achenbach SJ, Hanson CA, Marti GE, Call TG, Caporaso NE, Cerhan JR.

Cancer Epidemiol Biomarkers Prev. 2010 Apr;19(4):1098-102. doi: 10.1158/1055-9965.EPI-09-1217. Epub 2010 Mar 23.

34.

Monoclonal B-cell lymphocytosis (MBL): biology, natural history and clinical management.

Shanafelt TD, Ghia P, Lanasa MC, Landgren O, Rawstron AC.

Leukemia. 2010 Mar;24(3):512-20. doi: 10.1038/leu.2009.287. Epub 2010 Jan 21. Review.

35.

Single-cell analysis reveals oligoclonality among 'low-count' monoclonal B-cell lymphocytosis.

Lanasa MC, Allgood SD, Volkheimer AD, Gockerman JP, Whitesides JF, Goodman BK, Moore JO, Weinberg JB, Levesque MC.

Leukemia. 2010 Jan;24(1):133-40. doi: 10.1038/leu.2009.192. Epub 2009 Oct 15.

36.

Oligoclonal TRBV gene usage among CD8(+) T cells in monoclonal B lymphocytosis and CLL.

Lanasa MC, Allgood SD, Bond KM, Gockerman JP, Levesque MC, Weinberg JB.

Br J Haematol. 2009 May;145(4):535-7. doi: 10.1111/j.1365-2141.2009.07635.x. Epub 2009 Mar 2. No abstract available.

37.

Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemia.

Weinberg JB, Volkheimer AD, Chen Y, Beasley BE, Jiang N, Lanasa MC, Friedman D, Vaccaro G, Rehder CW, Decastro CM, Rizzieri DA, Diehl LF, Gockerman JP, Moore JO, Goodman BK, Levesque MC.

Am J Hematol. 2007 Dec;82(12):1063-70. Erratum in: Am J Hematol. 2008 Jan;83(1):90.

38.

Recurrent spontaneous abortion and skewed X-inactivation: is there an association?

Hogge WA, Prosen TL, Lanasa MC, Huber HA, Reeves MF.

Am J Obstet Gynecol. 2007 Apr;196(4):384.e1-6; discussion 384.e6-8.

PMID:
17403428
39.

The clinical use of karyotyping spontaneous abortions.

Hogge WA, Byrnes AL, Lanasa MC, Surti U.

Am J Obstet Gynecol. 2003 Aug;189(2):397-400; discussion 400-2.

PMID:
14520206
40.

A novel X chromosome-linked genetic cause of recurrent spontaneous abortion.

Lanasa MC, Hogge WA, Kubik CJ, Ness RB, Harger J, Nagel T, Prosen T, Markovic N, Hoffman EP.

Am J Obstet Gynecol. 2001 Sep;185(3):563-8.

PMID:
11568778
41.

X chromosome defects as an etiology of recurrent spontaneous abortion.

Lanasa MC, Hogge WA.

Semin Reprod Med. 2000;18(1):97-103. Review.

PMID:
11299525
42.

Highly skewed X-chromosome inactivation is associated with idiopathic recurrent spontaneous abortion.

Lanasa MC, Hogge WA, Kubik C, Blancato J, Hoffman EP.

Am J Hum Genet. 1999 Jul;65(1):252-4. No abstract available.

43.

Sex Chromosome Genetics '99. The X chromosome and recurrent spontaneous abortion: the significance of transmanifesting carriers.

Lanasa MC, Hogge WA, Hoffman EP.

Am J Hum Genet. 1999 Apr;64(4):934-8. Review. No abstract available.

Supplemental Content

Loading ...
Support Center